Merrion Pharmaceuticals Articles
Novo Nordisk buys rights to Emisphere technology for oral insulin for $57.5 million; enters deal with Merrion Pharma
22 December 2010
Showing 1-2 of 2 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
